Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 27, 2025
Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32-Week Randomized Phase 1b Multiple Ascending-Dose Trial.
Journal: Clinical pharmacology and therapeutics
Published: February 20, 2025
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 22, 2022
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 14, 2020
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Journal: The Lancet. Neurology
Published: January 15, 2019
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Journal: The Lancet. Neurology
Published: October 23, 2017
Population-Based Pharmacokinetic and Exposure-Efficacy Analyses of Peginterferon Beta-1a in Patients With Relapsing Multiple Sclerosis.
Journal: Journal of clinical pharmacology
Published: October 06, 2016
Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients.
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: February 18, 2016
Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.
Journal: British journal of clinical pharmacology
Published: July 22, 2014
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: July 08, 2014
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Journal: BMC neurology
Published: July 03, 2014
Last Updated: 09/26/2026